These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353 [TBL] [Abstract][Full Text] [Related]
27. C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. Yoshida Y; Sugimoto T; Hosokawa Y; Suma H; Kobayashi H; Ishitoku M; Kohno H; Tokunaga T; Watanabe H; Mokuda S; Nojima T; Hirata S; Sugiyama E Mod Rheumatol; 2022 Jan; 32(1):141-148. PubMed ID: 33775207 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis. Espinosa G; Simeón CP; Plasín MÁ; Xaubet A; Muñoz X; Fonollosa V; Cervera R; Vilardell M Arch Bronconeumol; 2011 May; 47(5):239-45. PubMed ID: 21458128 [TBL] [Abstract][Full Text] [Related]
29. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. Griffiths B; Miles S; Moss H; Robertson R; Veale D; Emery P J Rheumatol; 2002 Nov; 29(11):2371-8. PubMed ID: 12415594 [TBL] [Abstract][Full Text] [Related]
30. Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis. Toyama T; Asano Y; Takahashi T; Aozasa N; Akamata K; Noda S; Taniguchi T; Ichimura Y; Sumida H; Tamaki Z; Masui Y; Tada Y; Sugaya M; Sato S; Kadono T J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):337-44. PubMed ID: 22211766 [TBL] [Abstract][Full Text] [Related]
31. Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Štorkánová H; Oreská S; Špiritović M; Heřmánková B; Bubová K; Komarc M; Pavelka K; Vencovský J; Distler JHW; Šenolt L; Bečvář R; Tomčík M Sci Rep; 2021 Jan; 11(1):1. PubMed ID: 33414495 [TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824 [TBL] [Abstract][Full Text] [Related]
33. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. Ueda T; Sakagami T; Kikuchi T; Takada T Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675 [TBL] [Abstract][Full Text] [Related]
34. Interstitial Lung Disease: How Should Therapeutics Be Implemented? Bruni C; Campochiaro C; de Vries-Bouwstra JK Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835 [TBL] [Abstract][Full Text] [Related]
35. Serum LL-37 levels correlate with the efficacy of i.v. cyclophosphamide pulse for skin sclerosis and interstitial lung disease in systemic sclerosis. Takahashi T; Asano Y; Taniguchi T; Yoshizaki A; Sato S J Dermatol; 2017 Apr; 44(4):468-469. PubMed ID: 28378437 [No Abstract] [Full Text] [Related]
36. Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. De Luca G; Bosello SL; Berardi G; Rucco M; Canestrari G; Correra M; Mirone L; Forni F; Di Mario C; Danza FM; Pirronti T; Ferraccioli G Rheumatology (Oxford); 2015 Nov; 54(11):1991-9. PubMed ID: 26106211 [TBL] [Abstract][Full Text] [Related]
37. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis. Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307 [TBL] [Abstract][Full Text] [Related]
39. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. Furuya Y; Kuwana M J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489 [TBL] [Abstract][Full Text] [Related]
40. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Sabnani I; Zucker MJ; Rosenstein ED; Baran DA; Arroyo LH; Tsang P; Zubair M; Rivera V Rheumatology (Oxford); 2009 Jan; 48(1):49-52. PubMed ID: 18815156 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]